Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP

VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio) and higher dividend yield (2%), making it better for long-term buy-and-hold investors. Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (41% vs 31%) with more balanced U.S.-focused holdings, but charges higher fees (0.58%) and offers lower yield (0.9%).

10/02/2026, 8:13 PM • The Motley Fool

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion will present new immune profiling data from its phase 2 trial of personalized cancer vaccine EVX-01 combined with pembrolizumab at the SITC 2026 Annual Meeting in November. The data will showcase systemic immunomodulatory effects beyond vaccine-specific T-cell responses. Previous two-year data showed a 75% objective response rate in advanced melanoma patients, with 92% still responding at two-year follow-up and no relapses observed.

10/02/2026, 9:00 AM • GlobeNewswire

Prediction: Moderna Stock Will Soar 100% by 2030

Moderna has rebounded from pandemic-era lows with a diversified product portfolio including COVID, RSV, and flu vaccines, plus promising oncology pipeline candidates. The analyst predicts 100% stock appreciation by 2030 based on potential revenue growth to ~$3 billion and positive pipeline data, though acknowledges manufacturing challenges for personalized cancer vaccines and current high valuation multiples.

09/30/2026, 2:05 PM • The Motley Fool

Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities

The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.

09/30/2026, 4:58 AM • GlobeNewswire

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.

09/30/2026, 4:54 AM • GlobeNewswire

Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two pharmaceutical giants with divergent strategies: Bristol Myers Squibb, a deep-value dividend payer trading at cheap multiples (P/E 14.07) with flat revenue but stabilizing earnings, versus Eli Lilly, a high-growth juggernaut riding explosive success in GLP-1 metabolic drugs with 45% revenue growth and a P/E of 40.26. Despite BMY's attractive valuation, the author recommends LLY for 2026 due to its strong growth trajectory, successful drug pipeline including Retatrutide and lipoprotein(a) therapeutics, and forecast for 30% revenue growth.

09/29/2026, 6:22 PM • The Motley Fool

Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?

Moderna's stock has surged over 550% in 2026 following positive Phase 3 trial results for intismeran, a personalized cancer vaccine developed with Merck for melanoma treatment. Despite the excitement and analyst upgrades, the author argues the stock is overvalued at current levels (~$200), with consensus price targets around $77, and cautions against buying at these valuations.

09/28/2026, 10:28 AM • The Motley Fool

The Schwab U.S. Dividend Equity ETF Is Near Its All-Time High: Is It Still a Good Buy?

The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22% this year and hit an all-time high, prompting questions about valuation. Despite the gains, the ETF maintains a reasonable price-to-earnings multiple of less than 20 (below the S&P 500's 23) and offers a 3% dividend yield, making it still attractive for income-focused investors seeking safety and quality dividend stocks.

09/22/2026, 12:10 PM • The Motley Fool

Should You Invest $1,000 in SCHD Right Now?

The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22.8% year-to-date in 2026, outperforming the S&P 500's 11.8% gain. The rotation toward value and dividend stocks is expected to continue due to inflation concerns, higher interest rates, strong corporate earnings growth, and shrinking valuations. The ETF's focus on high-quality dividend-paying stocks positions it well for further gains.

09/22/2026, 5:20 AM • The Motley Fool

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder

Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year, offsetting concerns about patent expirations on legacy drugs. With a 3.95% dividend yield, $5B buyback program, and potential acquisition interest from AstraZeneca, analysts see significant upside potential as the market has underpriced the stock relative to its pipeline execution.

09/20/2026, 8:30 AM • The Motley Fool

Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth Opportunities

The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.

09/15/2026, 6:40 AM • GlobeNewswire

Parexel to Lead Sessions at DPHARM 2026 on AI, Talent and the Future of Clinical Operations

Parexel announced it will lead three expert panel sessions at DPHARM 2026 in Boston on enterprise AI adoption, workforce readiness, and patient-centric drug development. The company showcased its proprietary ParexelAI suite, which has delivered significant efficiency gains including 50% reduction in site selection timelines, 30% reduction in clinical study report preparation time, and 60% reduction in safety literature screening. CEO Peyton Howell and other executives will moderate discussions with leaders from major pharmaceutical companies including AbbVie, AstraZeneca, Boehringer Ingelheim, Regeneron, and Merck.

09/14/2026, 9:00 AM • GlobeNewswire

1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a core holding for long-term investors seeking diversified dividend income. With a 3% dividend yield (three times higher than S&P 500 ETFs), low 0.06% expense ratio, and exposure to stable sectors like healthcare and consumer staples, SCHD offers attractive passive income potential. The ETF has delivered 29% total returns year-to-date and is particularly suitable for tax-advantaged accounts like Roth IRAs.

09/08/2026, 2:37 PM • The Motley Fool

Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.

09/08/2026, 2:30 PM • The Motley Fool

Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight

The chronic myeloid leukemia (CML) clinical trial pipeline shows robust activity with 25+ pharmaceutical companies developing 25+ pipeline drugs. Key players including Merck, Enliven Therapeutics, ImmunoForge, and others are advancing promising therapies like TERN-701, ELVN-001, and KF1601 across various clinical stages. The market is evolving from established tyrosine kinase inhibitors toward newer selective agents targeting resistance, intolerance, and treatment-free remission.

09/08/2026, 1:00 PM • GlobeNewswire